DE69723434D1 - Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope - Google Patents

Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope

Info

Publication number
DE69723434D1
DE69723434D1 DE69723434T DE69723434T DE69723434D1 DE 69723434 D1 DE69723434 D1 DE 69723434D1 DE 69723434 T DE69723434 T DE 69723434T DE 69723434 T DE69723434 T DE 69723434T DE 69723434 D1 DE69723434 D1 DE 69723434D1
Authority
DE
Germany
Prior art keywords
vaccines
epitope
cell
present
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69723434T
Other languages
English (en)
Other versions
DE69723434T2 (de
Inventor
Der Burg Henricus Van
Martin Kast
Everardus Toes
Rienk Offringa
Johannes Melief
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Leiden
Seed Capital Investments (SCI) BV
Original Assignee
Universiteit Leiden
Seed Capital Investments (SCI) BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Leiden, Seed Capital Investments (SCI) BV filed Critical Universiteit Leiden
Publication of DE69723434D1 publication Critical patent/DE69723434D1/de
Application granted granted Critical
Publication of DE69723434T2 publication Critical patent/DE69723434T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69723434T 1996-04-26 1997-04-28 Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope Expired - Fee Related DE69723434T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP96201145 1996-04-26
EP96201145 1996-04-26
EP96203670 1996-12-23
EP96203670 1996-12-23
PCT/NL1997/000229 WO1997041440A1 (en) 1996-04-26 1997-04-28 Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes

Publications (2)

Publication Number Publication Date
DE69723434D1 true DE69723434D1 (de) 2003-08-14
DE69723434T2 DE69723434T2 (de) 2004-05-19

Family

ID=26142751

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69723434T Expired - Fee Related DE69723434T2 (de) 1996-04-26 1997-04-28 Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope

Country Status (11)

Country Link
US (1) US20070025968A1 (de)
EP (1) EP0900380B1 (de)
JP (1) JP4108126B2 (de)
AT (1) ATE244891T1 (de)
AU (1) AU738649B2 (de)
CA (1) CA2252675A1 (de)
DE (1) DE69723434T2 (de)
DK (1) DK0900380T3 (de)
ES (1) ES2205209T3 (de)
PT (1) PT900380E (de)
WO (1) WO1997041440A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
CA2295321C (en) * 1997-06-23 2008-01-29 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to hla molecules, and the use thereof
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
GB9804121D0 (en) * 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
ES2249907T3 (es) * 1998-05-23 2006-04-01 Leiden University Medical Center Anticuerpos de union cd40 y peptidos ctl para el tratamiento de tumores.
AU4577899A (en) * 1998-06-17 2000-01-05 Epimmune, Inc. Hla binding peptides and their uses
ATE357526T1 (de) 1998-08-21 2007-04-15 Us Gov Health & Human Serv Modifizierte hcv peptid-impfstoffe
US6962790B1 (en) 1998-09-23 2005-11-08 University Of Massachusetts Medical Center Predictive assay for immune response
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
WO2001023577A2 (en) * 1999-09-30 2001-04-05 Institut Pasteur Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
DK1230268T3 (da) 1999-11-18 2010-02-08 Epimmune Inc Heteroklitiske analoger af klasse I-epitoper
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
KR100838507B1 (ko) * 1999-12-28 2008-06-17 에피뮨 인코포레이티드 최적화된 미니유전자 및 이에 의해 암호화된 펩타이드
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP2278023A1 (de) * 2000-04-28 2011-01-26 Mannkind Corporation Antigener peptide von Melan-A/MART-1 und deren verwendung als impfstoffe gegen Tumor
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
ES2454640T3 (es) 2000-08-03 2014-04-11 Johns Hopkins University Vacuna molecular que lleva unida un polipéptido de chaperona del retículo endoplasmático a un antígeno
US20030191063A1 (en) * 2000-08-21 2003-10-09 Wraith David Cameron Peptide selection method
EP1619207A3 (de) * 2000-09-01 2006-02-08 Epimmune Inc. HLA-A2.1- Bindungspeptide stammend von HCV und ihre Verwendung
WO2002077012A2 (en) 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1752160A3 (de) * 2001-04-06 2007-05-30 Mannkind Corporation Epitop-Sequenzen
JP2004535799A (ja) * 2001-05-18 2004-12-02 パウダージェクト ワクチンズ，インコーポレーテッド ワクチン組成物
CN101024842A (zh) 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
EP1644048B1 (de) 2003-05-05 2015-04-29 Johns Hopkins University Anti-krebs-dna-vakzine mit einer für plasmide kodierenden signalsequenz, mutiertes onkoprotein-antigen und hitzeschockprotein
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
JP2008044848A (ja) * 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
CA2594040A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP2023143A1 (de) 2007-08-06 2009-02-11 Boehringer Ingelheim Vetmedica Gmbh Immunogene Streptokokkus-Proteine
WO2009125394A1 (en) 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti human immunodeficiency antibodies and uses thereof
CN105999250B (zh) 2011-05-24 2020-03-10 生物技术Rna制药有限公司 用于癌症的个体化疫苗
MX2014001142A (es) 2011-07-29 2014-02-27 Selecta Biosciences Inc Nanoportadores sinteticos que generan respuestas inmunitarias humorales y de linfocitos t citotoxicos (ctl).
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN105175498A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 一种宫颈癌相关的热休克蛋白复合物及其应用
WO2019054409A1 (ja) * 2017-09-12 2019-03-21 国立大学法人北海道大学 Ｈｌａタンパク質に相互作用する物質のスクリーニング方法及びスクリーニング用キット
US20210254825A1 (en) * 2018-08-23 2021-08-19 GRID Powr Ltd. Process and Device for Improving of Synthesis and/or Flue Gas Velocity Field for Refuse Derived Fuel Applications
WO2020086927A1 (en) * 2018-10-26 2020-04-30 Saint Louis University Peptides for inducing heterosubtypic influenza t cell responses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) * 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
EP0692973A1 (de) * 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide beschichtete zellen als immunogene
AU7958994A (en) * 1993-10-05 1995-05-01 Ludwig Institute For Cancer Research Method for provoking immunity by peptides labelled with a photoactivatable group which binds to mhc molecules
WO1996022067A2 (en) * 1994-12-27 1996-07-25 United Biomedical, Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics

Also Published As

Publication number Publication date
AU738649B2 (en) 2001-09-20
US20070025968A1 (en) 2007-02-01
ATE244891T1 (de) 2003-07-15
CA2252675A1 (en) 1997-11-06
EP0900380A1 (de) 1999-03-10
EP0900380B1 (de) 2003-07-09
AU2410697A (en) 1997-11-19
JP4108126B2 (ja) 2008-06-25
JP2000510689A (ja) 2000-08-22
PT900380E (pt) 2003-12-31
ES2205209T3 (es) 2004-05-01
WO1997041440A1 (en) 1997-11-06
DE69723434T2 (de) 2004-05-19
DK0900380T3 (da) 2003-11-03

Similar Documents

Publication Publication Date Title
DE69723434D1 (de) Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
Widmann et al. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides
CN111440229B (zh) 新型冠状病毒t细胞表位及其应用
RU95105991A (ru) Конъюгат, вакцина, способы усиления иммуногенности, способы иммунизации
HUP0402048A2 (hu) Eljárás specifikus patogének antigénjeinek azonosítására, izolálására és előállítására
Lachmann et al. Raising antibodies by coupling peptides to PPD and immunizing BCG‐sensitized animals
DE69940775D1 (de) Peptidzusammensetzung als immunogen zur allergiebehandlung.
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
CA2290485A1 (en) Method for the production of non-immunogenic proteins
EP0794797A4 (de) Methoden und zubehör zur immunisierung von wirtsorganismen durch verabreichung nackter polynucleotide , welche für antigene peptide codieren
DK0950068T3 (da) Kollagen-bindende proteinsammensatninger og fremgangsmade til anvendelse
GB2255093A (en) Hiv-1 core protein fragments
DE69716240D1 (de) Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten
AU7752487A (en) Immunomodulating compositions and their use
Oswald et al. Interleukin-12 synthesis is a required step in trehalose dimycolate-induced activation of mouse peritoneal macrophages
DE60229659D1 (de) Antigen-raster enthaltend rankl zur behandlung von knochenerkrankungen
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
Grasse et al. GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine
Salabert et al. Intradermal injection of an anti‐Langerin‐HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo
Gu et al. A multiple antigen peptide vaccine containing CD4+ T cell epitopes enhances humoral immunity against Trichinella spiralis infection in mice
GB2355983A (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
Bittner‐Eddy et al. Identification of gingipain‐specific I‐A b‐restricted CD 4+ T cells following mucosal colonization with P orphyromonas gingivalis in C 57 BL/6 mice
EP0753009A1 (de) Malariapeptide
AU707083B2 (en) Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
Ricciardi et al. Immune mechanisms involved in schistosoma mansoni-Cathepsin B vaccine induced protection in mice

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee